IP Library Granted Patent US 8,628,756
Granted Patent B2
US 8,628,756 · App. 12/159,584 · Granted Jan 14, 2014

Arginine heteromers for topical administration

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,628,756
App. No.
12/159,584
Granted
Jan 14, 2014
Kind
B2
Abstract

The invention is directed to a strategy for providing therapeutic or cosmetic benefit to skin by topically applying arginine chemically bound to a second (non-oligo arginine) compound in order to increase transepithelial delivery of arginine through a combination of increased solubility and flux across the skin. The arginine heteromers of the invention can add other complementary or beneficial properties for the skin beyond those that are arginine-related.

Claims (44)

1. A heteromer of formula I:

A-R  I

wherein A is arginine covalently bonded to a second compound R such that the guanadino group of the arginine remains unreacted,

wherein the covalent bond between A and R is an ether or carbamide linkage,

wherein R is an organic molecule selected from the group consisting of vitamins, fatty acids, and retinoids, and

wherein the heteromer has greater flux across the skin than arginine alone.

2. The heteromer according to claim 1 , wherein R is a vitamin.

3. The heteromer according to claim 2 , wherein R is vitamin C.

4. The heteromer according to claim 2 , wherein R is vitamin E.

5. The heteromer according to claim 2 , wherein R is vitamin D.

6. The heteromer according to claim 1 , wherein R is a fatty acid.

7. The heteromer according to claim 6 , wherein R is palmitic acid or caprylic acid.

8. The heteromer according to claim 1 , wherein R is a retinoid.

9. A composition comprising a cosmetically or dermatologically acceptable carrier; and the heteromer according to claim 1 .

10. The composition according to claim 9 , wherein R is a vitamin.

11. The composition according to claim 10 , wherein R is vitamin C.

12. The composition according to claim 10 , wherein R is vitamin E.

13. The composition according to claim 10 , wherein R is vitamin D.

14. The composition according to claim 9 , wherein R is a fatty acid.

15. The composition according to claim 14 , wherein R is palmitic acid or caprylic acid.

16. The composition according to claim 9 , wherein R is a retinoid.

17. The composition according to claim 9 , further comprising skin-care preparations.

18. The composition according to claim 9 , further comprising bath-preparations.

19. The composition according to claim 9 , further comprising cosmetic preparations.

20. The composition according to claim 9 , further comprising eye-care preparations.

21. The composition according to claim 9 , further comprising lip-care preparations.

22. The composition according to claim 9 , further comprising sunscreen preparations.

23. The composition according to claim 9 , further comprising hair care preparations.

24. The composition according to claim 9 , further comprising an anti-acne preparation.

25. The composition according to claim 9 , further comprising anti-oxidant preparations.

26. The composition according to claim 9 , further comprising anti-psoriasis preparations.

27. The composition according to claim 9 , further comprising corticosteroid preparations.

28. A method for providing a beneficial effect to skin comprising: topically applying a composition comprising the heteromer according to claim 1 .

29. The method according to claim 28 , wherein the beneficial effect is promoting angiogenesis in hair follicles.

30. The method according to claim 28 , wherein the beneficial effect is reducing signs of skin aging.

31. The method according to claim 28 , wherein the beneficial effect is reducing symptoms of acne.

32. The method according to claim 28 , wherein the beneficial effect is reducing damage caused by exposure of the skin to sunlight.

33. The method according to claim 28 , wherein the beneficial effect is reducing the appearance of fine lines and wrinkles in the skin.

34. The method according to claim 28 , wherein the beneficial effect is reducing glandular secretions.

35. The method according to claim 28 , wherein the beneficial effect is providing an anti-oxidant to the skin.

36. The method according to claim 28 , wherein the composition is applied to smooth the texture of skin.

37. The method according to claim 28 , wherein the composition is applied to provide moisturizing and lubricating benefit in the skin.

38. The method according to claim 28 , wherein the second compound is palmitic acid.

39. The method according to claim 38 , wherein the composition is applied to smooth the texture of skin.

Assignments (10)
SECURITY INTEREST Recorded Feb 17, 2025
From: REVANCE THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 070239/0739 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2025
From: ATHYRIUM BUFFALO LP
To: REVANCE THERAPEUTICS, INC
Reel/Frame 070153/0630 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; BELLUS MEDICAL, LLC; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0736 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0663 →
SECURITY INTEREST Recorded Mar 18, 2022
From: REVANCE THERAPEUTICS, INC.
To: ATHYRIUM BUFFALO LP
Reel/Frame 059437/0654 →
RELEASE OF SECURITY INTEREST Recorded Sep 27, 2019
From: HERCULES CAPITAL, INC. (F/K/A HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 050565/0300 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 24432/321, 24432/284, 24432/317, 22432/187, AND 22756/549 Recorded Oct 4, 2011
From: LEADER VENTURES, LLC
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 027015/0658 →
SECURITY AGREEMENT Recorded Sep 22, 2011
From: REVANCE THERAPEUTICS, INC.
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 026953/0726 →
SECURITY AGREEMENT Recorded May 24, 2010
From: REVANCE THERAPEUTICS, INC.
To: LEADER VENTURES, LLC
Reel/Frame 024432/0187 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2008
From: WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 021662/0548 →